Guardant Health (NASDAQ:GH) CEO Helmy Eltoukhy Sells 90,565 Shares

Guardant Health, Inc. (NASDAQ:GH) CEO Helmy Eltoukhy sold 90,565 shares of the business’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $103.82, for a total transaction of $9,402,458.30. Following the transaction, the chief executive officer owned 2,047,143 shares in the company, valued at approximately $212,534,386.26. The trade was a 4.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Guardant Health Price Performance

Shares of GH stock opened at $97.47 on Thursday. The stock has a market cap of $12.29 billion, a P/E ratio of -30.36 and a beta of 1.58. The company has a fifty day moving average price of $90.87 and a two-hundred day moving average price of $66.79. Guardant Health, Inc. has a one year low of $29.91 and a one year high of $112.43.

Guardant Health (NASDAQ:GH) last issued its earnings results on Wednesday, October 29th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.09. The business’s quarterly revenue was up 38.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.88) earnings per share. As a group, equities research analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on GH shares. Wells Fargo & Company boosted their target price on Guardant Health from $93.00 to $120.00 and gave the stock an “overweight” rating in a report on Monday. Guggenheim upped their price objective on shares of Guardant Health from $56.00 to $67.00 and gave the company a “buy” rating in a report on Thursday, September 25th. Citigroup raised their target price on shares of Guardant Health from $100.00 to $135.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Wolfe Research raised shares of Guardant Health from a “peer perform” rating to an “outperform” rating and set a $75.00 target price for the company in a report on Thursday, September 25th. Finally, William Blair reissued an “outperform” rating on shares of Guardant Health in a report on Thursday, September 25th. Twenty-three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $95.52.

Institutional Trading of Guardant Health

Several hedge funds and other institutional investors have recently bought and sold shares of GH. Allworth Financial LP lifted its position in shares of Guardant Health by 19.5% during the 3rd quarter. Allworth Financial LP now owns 844 shares of the company’s stock worth $53,000 after buying an additional 138 shares during the last quarter. TD Waterhouse Canada Inc. lifted its holdings in shares of Guardant Health by 3.2% in the third quarter. TD Waterhouse Canada Inc. now owns 4,891 shares of the company’s stock worth $306,000 after acquiring an additional 151 shares during the last quarter. Signaturefd LLC boosted its stake in shares of Guardant Health by 50.5% in the 2nd quarter. Signaturefd LLC now owns 635 shares of the company’s stock valued at $33,000 after purchasing an additional 213 shares in the last quarter. American Century Companies Inc. grew its holdings in shares of Guardant Health by 0.3% during the 1st quarter. American Century Companies Inc. now owns 104,206 shares of the company’s stock valued at $4,439,000 after purchasing an additional 282 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its position in Guardant Health by 8.3% during the 3rd quarter. PNC Financial Services Group Inc. now owns 4,016 shares of the company’s stock worth $251,000 after purchasing an additional 307 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.